

## Lipid Profile Status in Mustard Lung Patients and Its Relation to Severity of Airflow Obstruction

Davood Attaran<sup>1</sup>, Mohammad Towhidi<sup>1</sup>, Shahrzad M. Lari<sup>2\*</sup>, Hossein Ayatollahi<sup>3</sup>, Abbas Asadi<sup>4</sup>, Majid Ghayour-Mobarhan<sup>5</sup>, Omid Shadkam<sup>4</sup>, Zahra Maghami<sup>6</sup>

<sup>1</sup> Pulmonologist, COPD Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>2</sup> Pulmonologist, Cardio-Thoracic Surgery & Transplant Research Center, Emam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>3</sup> Pathologist, Cancer Molecular Pathology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>4</sup> Internist, COPD Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>5</sup> Clinical Nutritionist, Biochemistry and Nutrition Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>6</sup> General Practitioner, COPD Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

### ARTICLE INFO

Article type:  
Original article

Article history:  
Received: 14 Nov 2013  
Revised: 17 Dec 2013  
Accepted: 2 Jan 2014

Keywords:  
Chronic Obstructive Pulmonary Disease  
Lipid Profile  
Spirometry  
Sulfur Mustard

### ABSTRACT

**Introduction:** Chronic obstructive pulmonary disease (COPD) secondary to sulfur mustard gas poisoning, known as mustard lung, is a major late pulmonary complications in chemical warfare patients. Serious comorbidities like dyslipidemia are frequently encountered in COPD. The aim of this study was to measure the serum lipid profile and evaluate the relation of lipid parameters with the severity of airway obstruction in mustard lung patients.

**Materials and Methods:** Thirty-six non-smoker mustard lung patients with no history of cardiovascular disease, diabetes mellitus, and dyslipidemia were entered into this cross-sectional study. Control group consisted of 36 healthy non-smoker men were considered in this study. Serum lipid profile was performed in the patients and the controls. Spirometry was done in mustard lung patients.

**Results:** The mean age of the patients was  $47 \pm 6.80$  SD years. The mean duration of COPD was  $18.50 \pm 7.75$  SD years. There were statistically significant differences in mean serum triglycerides and total cholesterol levels between patients and controls ( $P=0.04$  and  $P=0.03$ , respectively). The mean levels of lipid parameters were not statistically significant different among the 4 stages of COPD severity ( $P>0.05$ ).

**Conclusion:** The current study revealed that the serum levels of triglycerides and cholesterol are elevated in mustard lung patients compared with the healthy controls. Since lipid profile abnormalities are considered as a major risk factor for cardiovascular disease, especial attention to this matter is recommended in mustard lung patients.

► Please cite this paper as:

Attaran D, Towhidi M, M. Lari Sh, Ayatollahi H3, Asadi A, Ghayour-Mobarhan M, Shadkam O, Maghami Z. Lipid Profile Status in Mustard Lung Patients and Its Relation to Severity of Airflow Obstruction. J Cardiothorac Med. 2014; 2(1): 113-117.

### Introduction

Sulfur mustard (SM) as a toxic alkylating gas and chemical warfare agent, can cause serious

late pulmonary complications including: asthma, bronchiectasis, bronchiolitis obliterans, pulmon-

\*Corresponding author: Shahrzad M.Lari, Cardio- Thoracic Surgery & Transplant Research Center, Emam Reza Hospital, Faculty of medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Tel: +98 511 8594083; Fax: +98 511 845 2146; E-mail: larish@ mums.ac.ir

© 2014 mums.ac.ir All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ary fibrosis, and chronic obstructive pulmonary disease (COPD) (1-3). COPD due to SM poisoning, known as "Mustard Lung", is one of the important late pulmonary concerns in chemical warfare patients (4, 5). COPD is characterized by irreversible airflow obstruction in response of the lungs to inhalatory noxious gases (6). COPD is considered to be the third leading cause of death by A2020 (7). It is well accepted that COPD is not confined to the lungs and is now considered as a systemic inflammatory condition (8) and inflammatory biomarkers like highly sensitive C-reactive protein (hs-CRP), interleukins (IL), etc may be related to the pathogenesis of COPD (9). The role of systemic inflammation in mustard lung is still a matter of debate. Previous studies in mustard lung patients have shown that inflammatory biomarkers like hs-CRP and IL-6, are elevated in patients and have related to severity of airway disease (1, 9). In relation to systemic inflammation, several comorbidities like hypertension, diabetes mellitus, dyslipidemia, and cardiovascular disease are associated with COPD (10). Cardiovascular disease is the most common cause of mortality in COPD patients and dyslipidemia is considered a major risk factor for cardiovascular disease (10). The exact prevalence of lipid profile abnormalities in COPD are not determined (11). Previous studies in COPD patients have shown that the prevalence of dyslipidemia is significantly higher in COPD patients comparing to the healthy controls (7). The possible mechanisms of lipid profile abnormalities in COPD are: systemic inflammation, smoking, and physical inactivity (12, 13). The frequency of lipid profile abnormalities in mustard lung patients is not defined yet. Recently a study in chemical warfare patients has shown that serum total cholesterol (TC) and triglycerides (TG) are increased comparing to the healthy controls (14). Since smoking per se can cause major changes in serum lipid profile and as smoking is a major risk factor in COPD, the evaluation of serum lipid abnormalities in non-smoker COPD patients seems to be necessary.

This study was performed to evaluate the serum lipid profile in non-smoker mustard lung patients and to compare the results with the normal healthy controls. Also we aimed to determine the possible correlation of serum lipid abnormalities with severity of airway obstruction.

## Materials and Methods

Thirty-six mustard lung patients who had documented SM poisoning history entered into this cross-sectional study from April 2012 to September 2012, Ghaem Hospital, Mashhad, Iran. All the participants were male. According to the

definition of American Thoracic Society (ATS), patients who had irreversible airway obstruction [(forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) less than 70% after 400 µgr Salbutamol inhalation] were considered to have COPD (15). One respiratory physician visited all patients. The patients were excluded if they had Asthma, bronchiectasis, tuberculosis, acute pulmonary infection, cardiovascular disorder and other systemic illnesses (e.g. diabetes mellitus, dyslipidemia); if they were taking systemic steroid, lipid lowering agents; if they had COPD exacerbation or hospitalization during the last 2 months; and if they were current or ex-smoker. Body mass index (BMI) was calculated as weight (kg) to height (m<sup>2</sup>). By standard spirometric techniques FEV1, FVC and FEV1/FVC were measured (multifunctional spirometer HI-801; chest MI Inc, Tokyo, Japan). The severity of COPD was evaluated according based on GOLD (global initiative for chronic obstructive lung disease) guidelines (6) as following:

Stage 1 (mild): FEV1/FVC < 70%, FEV1 ≥ 80%

Stage 2 (moderate): FEV1/FVC < 70%, 50% ≤ FEV1 < 80%

Stage 3 (severe): FEV1/FVC < 70%, 30% ≤ FEV1 < 50%

Stage 4 (very severe): FEV1/FVC < 70%, FEV1 < 30%

Thirty-six healthy non-smoker men were considered as control group and the age and BMI of the controls were matched with patients. The control group was selected from Mashhad metabolic syndrome cohort study (16).

After 14 hours fasting, 5 milliliter blood samples were obtained from antecubital vein both in the patients and the controls. After centrifuge of blood samples, the serum samples were isolated and stored at -70 °C prior to analysis. Serum TG, TC, high density lipoprotein (HDL) were determined by routine enzymatic methods (Pars Azmoon, Tehran, Iran).

This study was approved by the Ethics Committee of the Mashhad University of Medical Sciences (MUMS), code number: 89456. All patients provided informed consent.

## Statistical analysis

The data were analyzed using statistical package for social sciences (SPSS, version 11.5, Chicago, IL, USA). For summarizing the clinical and biochemical findings of the groups, descriptive statistics were used. The continuous data were presented as percentages and means ± SDs. The normality of continuous variables was checked using the one sample Kolmogorov-Smirnov test. For continuous and categorical variables, independent student's t tests and chi-square tests were used to evaluate the statistical significance of any difference or relationship

**Table 1.** The clinical and biochemical findings in mustard lung patients and controls.

Data	Patients*	Controls*	P value**
Age (years)	47±6.80	46.50±6.10	0.53
BMI	26.50±4.55	25.80±4.35	0.80
TG(mg/dl)	181±41.80	130±64.50	0.04
TC(mg/dl)	210.40±34.55	160.23±45.60	0.03
LDL(mg/dl)	112.17±30.26	98.18±43.5	0.1
HDL(mg/dl)	46.23±4.95	42.34±5.5	0.5

\* Data are presented as mean±SD.

\*\*P value<0.05 was considered significant.

BMI: Body Mass Index, HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein, TC: Total Cholesterol, TG: Triglycerides.

between parameters, respectively. Pearson and Spearman correlation coefficients were calculated. A p Values less than 0.05 was considered significant.


## Results

The mean age of mustard lung patients was 47±6.80 SD years. The frequency of different GOLD stages is shown in Figure 1. The mean duration of COPD was 18.50±7.75 SD years. The mean FEV1 was 2.78±0.85 SD liter. Twenty-six patients (72%) were received inhaled corticosteroids (ICS) and 5 patients were on home oxygen therapy.

The clinical and biochemical findings in the patients and the controls are shown in Table 1. As it has shown in Table 1, there were statistically significant differences in mean TC and TG between the patients and the controls.

The correlation of FEV1 with TG, TC, LDL, and HDL are shown in Table 2 that were not significant. Additionally, There were no statistically significant differences in mean serum levels lipid profile among the GOLD stages [TG ( $P=0.20$ ), TC ( $P=0.07$ ), HDL ( $P=0.10$ ), and LDL ( $P=0.15$ )].

We calculate the TC/HDL in patients and 24 patients (66%) had a ratio >4. There was no statistically significant correlation between TC/HDL and FEV1 ( $r=0.15$ ,  $P=0.41$ ).



**Figure 1.** The frequency of different GOLD stages in patients. GOLD: Global initiative for Obstructive Lung Disease.

**Table 2.** The correlation of FEV1 with lipid profile parameters in mustard lung patients.

Parameter	P value*	Correlation Coefficient
TG(mg/dl)	0.65	0.20
TC(mg/dl)	0.42	0.25
LDL(mg/dl)	0.90	0.20
HDL(mg/dl)	0.50	0.10

\*  $P<0.05$  was considered significant.

HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein, TC: Total Cholesterol, TG: Triglycerides.

## Discussion

Since comorbidities have an important role in COPD morbidity and mortality, we evaluated the serum lipid profile in chemical warfare patients with COPD in this study. We found statistically significant differences in mean serum levels of TG and TC between the patients and the controls. The serum levels of TG, TC, LDL, and HDL did not have correlations with the severity of airflow limitation.

As we mentioned earlier, now COPD is considered a systemic inflammatory condition (8). The possible mechanisms of systemic inflammation are: genetic and constitutional factors, spillage of respiratory inflammatory mediators into systemic circulation, systemic inflammation involving the lungs, and smoking (17-20). In relation to systemic inflammatory condition in COPD, important comorbidities are highlighted in process of the disease. One of the main comorbidities in COPD is cardiovascular disease. Previous studies have shown that more than 50% of COPD patients have cardiovascular disease (10). COPD, independent of other major cardiovascular risk factors are associated with increased cardiovascular disease (21). The exact mechanism of increased cardiovascular risk in COPD is not defined yet (22), systemic inflammation and increased relevant biomarkers like hs-CRP may be concerned. The identified risk factors for accelerating atherosclerosis in cardiovascular system are: hypertension, diabetes mellitus,

hyperlipidemia especially high LDL and low HDL, and smoking (22). One of the most important risk factors in cardiovascular disease is dyslipidemia (10). The prevalence of lipid profile abnormalities in COPD are different in studies and a range of 9-50% have been reported (23-25). Studies concerning the prevalence of cardiovascular disease in chemical warfare patients have shown that coronary atherosclerotic lesion and coronary ectasia are frequent in patients comparing normal population (26, 27). Additionally, Attaran and colleagues show that the serum level of hs-CRP, as a major risk factor for ischemic heart disease, was increased in mustard lung patients comparing to healthy controls (9).

We found a statistically significant difference in mean serum levels of TG and TC between the patients and the controls. This finding was compatible with the results of Keramati and colleagues in chemical warfare patients who reported the same (14). Also Begun and colleagues showed that all lipid parameters including TG, TC, LDL, and HDL are elevated in COPD patients (22). Although there are studies that have shown the serum of lipid parameters are not different from healthy controls (10).

In the present study, the mean levels of lipid parameters were not different in different stages of COPD according to GOLD classification. The finding was compatible with the results of Niranjan and colleagues (12). Additionally we did not find any correlation between FEV1 and lipid parameters in mustard lung patients.

Our study has several limitations: First is our small sample size especially regarding to the distribution of patients in different severity stages. Second is about measurement of other lipid-related parameters like: Apo lipoproteins.

## Conclusion

Since the presence of significant comorbidities in COPD, in this study we evaluated the serum levels of lipid parameters in mustard lung patients. The serum levels of triglycerides and total cholesterol were significantly elevated comparing the healthy controls. The serum lipid profile did not correlate with the severity of COPD.

## Acknowledgement

This study was financially supported by MUMS (code number: 89456). The authors wish to thank M.Aalami for his wonderful assistance in performing this study.

## Conflict of Interest

The authors declare no conflict of interest.

## References

1. Attaran D, Lari SM, Towhidi M, Marallu HG, Ayatollahi H, Khajehdaluae M, et al. Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2010; 5:335-40.
2. Khateri S, Ghanei M, Keshavarz S, Soroush M, Haines D. Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. *J Occup Environ Med*. 2003; 45: 1136-43.
3. Balali-Mood M, Hefazi M. Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. *Basic Clin Pharmacol Toxicol*. 2006; 99:273-82.
4. Ghanei M, Harandi AA. Molecular and cellular mechanism of lung injuries due to exposure to sulfur mustard: a review. *Inhal Toxicol*. 2011; 23:363-71.
5. Ghanei M, Amiri S, Akbari H, Kosari F, Khalili AR, Alaeddini F, et al. Correlation of sulfur mustard exposure and tobacco use with expression (immunoreactivity) of p53 protein in bronchial epithelium of Iranian "mustard lung" patients. *Mil Med*. 2007; 172: 70-4.
6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. NHLBI/WHO Workshop Report, Executive Summary. 2004; 1-21.
7. Joo H, Park J, Lee SD, Oh YM. Comorbidities of chronic obstructive pulmonary disease in Koreans: a population-based study. *J Korean Med Sci*. 2012; 27:901-6.
8. Tkacova R. Systemic inflammation in chronic obstructive pulmonary disease: May adipose tissue play a role? *Reviwe of the literature and futur perspectives*. *Mediators Inflamm*. 2010; 2010: 585-989.
9. Attaran D, Lari SM, Khajehdaluae M, Ayatollahi H, Towhidi M, Marallu HG, et al. Highly sensitive C-reactive protein levels in Iranian patients with pulmonary complication of sulfur mustard poisoning and its correlation with severity of airway diseases. *Hum Exp Toxicol*. 2009; 28: 739-45.
10. Nillawar AN, Joshi KB, Patil SB, Bardapurkar JS, Bardapurkar SJ. Evaluation of HS-CRP and Lipid Profile in COPD. *J Clin Diagn Res*. 2013; 7:801-3.
11. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. *Proc Am Thorac Soc*. 2008; 5:549-55.
12. Niranjan MR, Dadapeer k, Rashmi B K. Lipoprotein profile in patients with chronic obstructive pulmonary disease in a tertiary care hospital in south India. *Journal of Clinical and Diagnostic Research*. 2011; 5: 990-3.
13. Waseem AMA, Hossain M, Rizvi SAA, Ahmad Z, Islam N. Oxidative stress and lipid profile in COPD patients: Beneficial role of exercise and scope for improvement. *Biomedical Research*. 2013; 24: 135-8.

14. Keramati MR, Balali-Mood M, Mousavi SR, Sadeghi M, Riahi-Zanjani B. Biochemical and hematological findings of Khorasan veterans 23 years after sulfur mustard exposure. *J Res Med Sci.* 2013; 18:855-9.
15. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 1995; 52: S77-S121.
16. Ebrahimi M, Kazemi-Bajestani SM, Ghayour-Mobarhan M, Moohebaty M, Paydar R, Azimi-Nezhad M, et al. Metabolic syndrome may not be a good predictor of coronary artery disease in the Iranian population: population-specific definitions are required. *Scientific World Journal.* 2009;9:86-96.
17. van Eeden SF, Tan WC, Suwa T, Mukae H, Terashima T, Fujii T, et al. Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM<sub>10</sub>). *Am J Respir Crit Care Med.* 2001; 164:826-30.
18. Barnes PJ. Chronic obstructive pulmonary disease. *N Engl J Med.* 2000; 27:269-80.
19. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2001; 164: 1008-11.
20. Rokni Yazdi H, Lari S, Attaran D, Ayatollahi H, Mohsenizadeh A. The serum levels of adiponectin and leptin in mustard lung patients. *Hum Exp Toxicol.* 2013. [Epub ahead of print]
21. Reed RM, Hashmi S, Eberlein M, Iacono A, Netzer G, DeFilippis A, et al. Impact of lung transplantation on serum lipids in COPD. *Respir Med.* 2011; 105:1961-8.
22. Begum K, Begum MK, Sarker ZH, Dewan MRK, Siddique MJH. Lipid Profile Status of Chronic Obstructive Pulmonary Disease in Hospitalized Patients Bangladesh *J Med Biochem.* 2010; 3: 42-5.
23. Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. *Chest.* 2005; 128: 2068-75.
24. Walsh JW, Thomashow BM: COPD and comorbidities: results of COPD Foundation national survey, Paper presented at: COPD and comorbidities: treating the whole patient. San Diego, CA: ATS 2006 San Diego International Conference; 2006:19-24.
25. García-Olmos L, Alberquilla A, Ayala V, García-Sagredo P, Morales L, Carmona M, et al. Comorbidity in patients with chronic obstructive pulmonary disease in family practice: a cross sectional study. *BMC Fam Pract.* 2013; 14:11.
26. Karbasi-Afshar R, Shahmari A, Madadi M, Poursaleh Z, Saburi A. Coronary angiography findings in lung injured patients with sulfur mustard compared to a control group. *Ann Card Anaesth.* 2013; 16:188-92.
27. Shabestari MM, Jabbari F, Gohari B, Moazen N, Azizi H, Moghiman T, et al. Coronary artery angiographic changes in veterans poisoned by mustard gas. *Cardiology.* 2011; 119:208-13.